Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 15, Number 6—June 2009

Dispatch

Methicillin-Resistant Staphylococcus aureus USA300 Clone in Long-Term Care Facility

Pierre Tattevin1, Binh An Diep, Michael Jula, and Françoise Perdreau-RemingtonComments to Author 
Author affiliations: Pontchaillou University Hospital, Rennes, France (P. Tattevin); San Francisco General Hospital, San Francisco, California, USA (B.A. Diep, M. Jula, F. Perdreau-Remington)

Main Article

Table

Analysis of MRSA clones obtained in a long-term care facility, San Francisco, California, USA, 1997–2006*

Clonal group Antimicrobial drug resistance, %
Specimen source, %
Ery Cli Cip Sxt Gen Tet SST Respiratory tract Urine Blood†
USA100 (n = 299) 96.2 84.9 95.9 3.3 16.9 2.6 22.7 36.4 35.1 5.8
USA300 (n = 182) 87.8 15.0 79.4 0.6 6.1 13.2 64.3 18.1 10.4 7.1
USA500 (n = 82) 84.7 27.8 71.7 28.2 20.8 6.0 30.5 28 31.7 9.8
LFT (n = 98) 87.3 65.6 62.8 10.9 13.4 7.8 37.2 26.6 26.6 9.6
All MRSA (n = 744) 91.8 64.6 87.0 7.1 21.6 5.1 32.7 25.1 23.1 6.3

*MRSA, methicillin-resistant Staphylococcus aureus; Ery, erythromycin; Cli, clindamycin; Cip, ciprofloxacin; Sxt, trimethoprim-sulfamethozazole; Gen, gentamicin; Tet, tetracycline; SST, skin and skin structure; LFT, low frequency types.
†Blood and other typically sterile sites.

Main Article

1Current affiliation: San Francisco General Hospital, San Francisco, California, USA.

TOP